RA Williams Distributors Limited reported a 15% revenue growth for the third quarter ending January 31, 2025, driven by strategic expansion and successful new product launches. 

As a leading distributor of pharmaceutical products and healthcare solutions across Jamaica, this strong performance highlights the company’s continued growth and market expansion.

The company recorded revenue of $438.9 million, a notable increase from $380.8 million in the same period last year. This growth reflects a strong demand for RA Williams’ products and its ability to remain competitive in the market. 

A key highlight of the quarter was the official launch of Iracet (Levetiracetam 500 mg), the first generic Levetiracetam available in Jamaica, now available through the National Health Fund’s Drug-Serv Pharmacies, expanding affordable access across the island. Additionally, the company introduced new products in partnership with Fourrts, including Cofex, an over-the-counter cough remedy, and Sucrafil and Sucrafil-O, treatments for ulcers and hyperacidity. 

RA Williams also marked the beginning of its collaboration with Ryvis by successfully launching two over-the-counter products, PregStop and GasStop, followed by ColdStop and DandZap Plus. Impressed by the company’s effective management of these products, Ryvis has now entrusted RA Williams with 21 additional prescription drugs. This expansion strengthens the company’s portfolio and is poised to drive significant revenue growth.

CEO Audley Reid shared, “Expanding access to essential medications remains a top priority for us, and the introduction of Iracet through the NHF is a significant step in making epilepsy treatment more affordable. Our growing portfolio, including new partnerships and an expanded Ryvis line, allows us to better serve patients in key therapeutic areas.”

The company also demonstrated resilience by effectively managing operational costs and strategically investing for future growth. The operating expense ratio stood at 40% with total assets increased by 56% year-over-year, a strong indicator of the company’s growth trajectory and the successful execution of strategic initiatives.

RA Williams achieved a gross profit margin of 46% for the quarter. Additionally, the company maintained profitability with a net profit margin of 3% reflecting the company’s ongoing commitment to cost discipline while continuing to expand its business.

Looking ahead, RA Williams remains confident in its ability to sustain growth through continued product portfolio expansion and strategic market positioning. Reid was keen to point out, “With the success of our product launches and the increase in revenue, we are well-positioned to continue delivering value to our stakeholders. We are committed to adapting to the evolving healthcare landscape, and as we build on this momentum, RA Williams will strengthen its position as a leading distributor of healthcare solutions in Jamaica.”